They need it for their early june usa biotech networking conference.
- trial fully enrolled
- no safety issues
- all participants still on
- tox study done with zero issues
- efficacy likely to show stabalisation or dare to say improvement
- works with exon skipping
- yet to partner with anyone
- inflammation now better understood to be key driver for best treatment outcomes
- show us the money
When US tox study due, page-7
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $74.82M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2409 | 8.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.4¢ | 1366 | 1 |
View Market Depth
| Last trade - 10.02am 04/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |
Day chart unavailable